Skip to main content

Table 3 The relationship between SGEF expression and clinicopathological features of LAC patients

From: SGEF is a potential prognostic and therapeutic target for lung adenocarcinoma

  SGEF  
Feature High (n = 54) Low (n = 38) P value
Gender    P = 0.192
 Male 33 (61.11%) 18 (47.37%)  
 Female 21 (28.89%) 20 (52.63%)  
Age at diagnosis    P = 0.781
 <60 20 (37.04%) 13 (34.21%)  
 ≥ 60 34 (62.96%) 25 (65.79%)  
Location    P = 0.407
 Left 21 (38.89%) 12 (31.58%)  
 Right 33 (61.11%) 26 (68.42%)  
EGFR status    P = 0.545
 Mutant 18 (33.33%) 15 (39.47%)  
 Wild type 36 (66.67%) 23 (60.53%)  
T stage    P = 0.028
T1–2 36 (66.66%) 33 (86.84%)  
T3–4 18 (33.34%) 5 (13.16%)  
N stage    P = 0.011
N0 21 (38.88%) 25 (65.79%)  
N1–3 33 (61.12%) 13 (34.21%)  
TNM stage    P < 0.001
 I 7 (12.96%) 18 (47.36%)  
 II + III 47 (87.04%) 20 (52.63%)  
Histological grade    P = 0.608
 Well 6 (11.11%) 5 (11.36%)  
 Moderate 42 (77.78%) 31 (70.45%)  
 Poor 6 (11.11%) 2 (4.54%)